Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 1, 2011, Pages 15-20

  Sasaki, Hidefumi ^a   Hikosaka, Yu ^a   Kawano, Osamu ^a   Moriyama, Satoru ^a   Yano, Motoki ^a   Fujii, Yoshitaka ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Copy number; FISH; Kras; Lung cancer; Mutation

Indexed keywords

K RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

EID: 78651109803     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31820594f0     Document Type: Article

References (35)

1. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Ins 2005;97:339-346.
2. Uchiyama M, Usami N, Kondo M, et al. Loss of heterozygosity of chromosome 12p does not corelate with Kras mutation in non-small cell lung cancer. Int J Cancer 2003;107:962-969.
3. Sasaki H, Okuda K, Kawano O, et al. Nras and Kras mutation in Japanese lung cancer patients: genotyping analysis using LightCycler. Oncol Rep, 2007, 18, 623-628.
4. Marks JL, Broderck S, Zhou Q, et al. Prognostic and therapeutic implications of EGFR and Kras mutations in resected lung adenocarcinoma. J Thorac Oncol 2008;3:111-116.
5. Pulciani S, Santos E, Long LK, et al. ras Gene amplification and malignant transformation. Mol Cell Biol 1985;5:2836-2841.
6. Schwab M, Alitalo K, Varmus HE, et al. A cellular oncogene (Cc-Kiras) is amplified, overexpressed, and located within karyotypic abnormalities in mouse adrenocortical tumour cells. Nature 1983;303:497-501.
7. Balsara BR, Sonoda G, du Manoir S, et al. Comparative genomic hybridization analysis detects frequent, often high-level, overrepresentation of DNA sequences at 3q, 5p, 7p, and 8q in human non-small cell lung carcinomas. Cancer Res 1997;57:2116-2120.
8. Jeuken J, van den Broecke C, Gijsen S, et al. RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathol 2007;114:121-133.
9. Kozma L, Kiss I, Nagy A, et al. Investigation of c-myc and K-ras amplification in renal clear cell adenocarcinoma. Cancer Lett 1997;111: 127-131.
10. Sakakura C, Mori T, Sakabe T, et al. Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridizations. Genes Chromosomes Cancer 1999;24:299-305.
11. Shiraishi M, Noguchi M, Shimosato M, et al. Amplification of protooncogenes in surgical specimens of human lung carcinomas. Cancer Res 1989;49:6474-6479.
12. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007;450:893-898.
13. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-1075.
14. Wagner PL, Perner S, Rickman DS, et al. In situ evidence of Kras amplification and association with increased p21 levels in non-small cell lung carcinoma. Am J Clin Pathol 2009;132:500-505.
15. Modrek B, Ge L, Pandita A, et al. Oncogenic activating mutations are associated with local copy gain. Mol Cancer Res 2009;7:1244-1252.
16. Sasaki H, Shimizu S, Okuda K, et al. Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer. Lung Cancer 2009;64:295-300.
17. Sasaki H, Endo K, Okuda K, et al. Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. J Cancer Res Clin Oncol 2008;134:569-577.
18. Endo K, Sasaki H, Yano M, et al. Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy. Oncol Rep 2006;16:533-541.
19. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-1500.
20. Sasaki H, Shimizu S, Endo K, et al. EGFR and ErbB2 mutation status in Japanese lung cancer patients. Int J Cancer 2005;118:180-184.
21. Endo K, Konishi A, Sasaki H, et al. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 2005;50:375-384.
22. Sasaki H, Endo K, Konishi A, et al. EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LighyCycler. Clin Cancer Res 2005;11:2924-2929.
23. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:6829-6837.
24. Okuda K, Sasaki H, Yukiue H, et al. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci 2008;99:2280-2285.
25. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-3807.
26. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-655.
27. Bos JL. Ras oncogènes in human cancer: a review. Cancer Res 1989; 49:4682-4689.
28. Diaz R, Lopez-Barcons L, Ahn D, et al. Complex effects of Ras proto-oncogenes in tumorigenesis. Carcinogenesis 2004;25:535-539.
29. Heidenbland M, Johnson T, Mahlamaki EH, et al. Detailed genomic mapping and expression analysis of 12p amplification in pancreatic carcinomas reveal a 3.5-Mb target région for amplification. Genes Chromosomes Cancer 2002;34:211-223.
30. Peng DF, Sugihara H, Mukaido K, et al. Alteration of chromosomal copy number during progression of diffuse-type gastric carcinomas: métaphase and array based comparative genomic hybridization analyses of multiple samples from individual tumors. J Pathol 2003;201:439-450.
31. Slebos RJ, Evers SG, Wagenaar SS, et al. Cellular protooncogenes are infrequently amplified in untreated non-small cell lung cancer. Br J Cancer 1989;59:76-80.
32. Serrano M, Lin AW, McCurrach ME, et al. Oncogenic ras provokes prématuré cell sénescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
33. Soh J, Okumura N, Lockwood WL, et al. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS ONE 2009;4:e7464.
34. Liu ML, Von Lintig FC, Liyanage M, et al. Amplification of Ki-ras and élévation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag trangenic mice. Oncogene 1998;17:2403-2411.
35. Singh A, Greninger P, Rhodes D, et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009;15:489-500.